Biotech Values

[poorgradstudent]

Re: CNAT

I would submit that the anachronism you’ve highlighted likely means Emricasan won’t end up being the best drug for liver disease; however, by no means does this imply that Emricasan won’t work (which is what your initial post in this thread seemed to be implying).

I don't disagree with that. If anything, my comments about pan-inhibition would relate more to safety considerations than efficacy.